Theravance Biopharma (TBPH) EBITDA Margin Growth (3y) (2016 - 2026)
Theravance Biopharma (TBPH) EBITDA Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9,942.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 530.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1,211.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 7,794.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - | 18,557.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,557.00 |
| Dec 31, 2025 | 16,261.00 |
| Sep 30, 2025 | 4,115.00 |
| Jun 30, 2025 | 23,285.00 |
| Mar 31, 2025 | 19,797.00 |
| Dec 31, 2024 | 32,674.00 |
| Sep 30, 2024 | 34,211.00 |
| Jun 30, 2024 | 38,627.00 |
| Mar 31, 2024 | 51,115.00 |
| Dec 31, 2023 | 37,286.00 |
| Sep 30, 2023 | 36,383.00 |
| Jun 30, 2023 | 36,365.00 |
| Mar 31, 2023 | 12,575.00 |
| Dec 31, 2022 | -8,959.00 |
| Sep 30, 2022 | 45,123.00 |
| Jun 30, 2022 | -16,459.00 |
| Mar 31, 2022 | 108,826.00 |
| Dec 31, 2021 | 2,212.00 |
| Sep 30, 2021 | 8,009.00 |
| Jun 30, 2021 | -28,898.00 |